

Comparative Effectiveness of Stone Surgery for Pediatric Patients: The PKIDS Trial

Gregory Tasian, MD, MSc, MSCE
Associate Professor of Surgery and Epidemiology
Children's Hospital of Philadelphia
University of Pennsylvania

Disclosures



Industry relationships

Scientific Advisory Board for Anylam Pharmaceuticals & NovoNordisk

Research funding from Anylam & NovoNordisk unrelated to presented work



Research funding

NIH/NIDDK

- R01 DK122156
- U01 DK110961
- P20 DK127488
- R56 DK136019

PCORI

PCORI 2018C3-14778

PCORI 203076

PA Department of Health

SAP #4100085749

Funding Acknowledgement

This work was supported through a Patient-Centered Outcomes Research Institute (PCORI) Program Award (CER-2018C3-14778).

Disclosures

All statements in this report, including its findings and conclusions, are solely those of the authors and do not necessarily represent the views of the Patient-Centered Outcomes Research Institute (PCORI), its Board of Governors or Methodology Committee.



Evidence base

Uncomplicated ureteral stones <10 mm, clinicians should offer observation with or w/o MET using α -blockers. **Level B**

URS or SWL for pediatric patients with ureteral stones unlikely to pass or who failed observation and/or MET, based on anatomy and body habitus. **Level B**

Clinicians should obtain a low-dose CT scan on pediatric patients prior to performing PCNL. **Level C**

In pediatric patients with ureteral stones, clinicians should not routinely place a stent prior to URS. **Expert Opinion**

In pediatric patients with a total renal stone burden ≤ 20 mm, clinicians may offer SWL or URS as first-line therapy. **Level C**

For total renal stone burden >20 mm, both PCNL and SWL are acceptable. If SWL is used, a ureteral stent or nephrostomy tube should be placed. **Expert Opinion**

Except in cases of coexisting anatomic abnormalities, open/laparoscopic/robotic surgery should not be routinely performed for upper tract stones. **Expert Opinion**

In pediatric patients with asymptomatic and non-obstructing renal stones, clinicians may utilize active surveillance with periodic ultrasonography. **Expert Opinion**

American Urological Association Guidelines

In pediatric patients with a total renal stone burden ≤ 20 mm, clinicians may offer SWL or URS as first-line therapy. **Level C**

For total renal stone burden >20 mm, both PCNL and SWL are acceptable. If SWL is used, a ureteral stent or nephrostomy tube should be placed. **Expert Opinion**

PKIDS




Pediatric KIDney Stone
Care Improvement Network



Children's of Alabama®




Kids deserve the best.



Mission


To improve the health of children with kidney stone disease through collaborative patient-centered research

Surgical Learning Cycle



Embracing Partnerships

- Patients
- Caregivers
- Clinicians
- Industry
- Payers
- Healthcare system leaders



After surgery the experience can be drastically different:

“The outcome was that this was a surgery that no one wanted to repeat.”



“Wow! This experience was so different than my previous one.”







Research question

What is the best surgery for my child who has a kidney or ureteral stone?


Ureteroscopy (URS)




Shockwave lithotripsy (SWL)



Percutaneous nephrolithotomy (PCNL)





Study Design

Prospective observational cohort study



Population

Broad Eligibility Criteria

Inclusion


- Males or females, 8-21 years of age, undergoing URS, SWL, or PCNL for the removal of at least one kidney and/or ureteral stone

Exclusion


- Participants for whom informed consent would confer additional risk (e.g., obstructing ureteral stone with fever requiring emergency surgery)

Comparators


Ureteroscopy (URS)



Shockwave lithotripsy (SWL)



Percutaneous nephrolithotomy (PCNL)



Outcomes: Patient selected and prioritized

Primary Outcome: Stone clearance


HTE by stone size and stone location

- Absence of any stone >4mm
- Standardized ultrasound at 6 +/- 2 weeks

Secondary: Physical, social, and emotional health

HTE by age and sex

- PROMIS measures
 - Pain intensity
 - Pain interference
 - Anxiety
 - Sleep disturbance
 - Psychological stress
 - Peer relationships
- Urinary symptoms
 - DVSS
 - QUIKSS
- Missed school/work
- ED visits, repeat surgery, admissions



* All boxes in grey shade reflect clinical care (not study) procedures.

Analysis

Propensity score development

- Identify patient, surgeon, and institutional characteristics that could impact selection of treatment and outcomes
 - Clinician importance
 - Principal components analysis
 - Correlation

Inverse propensity score weighting to balance patient, surgeon, and institutional characteristics across groups

- Weighted generalized linear models for stone clearance
- Weighted ANCOVA for PROs

Analysis


Multiple imputation for missing data

Centralized review of random sample of 10% of pre- and post-operative ultrasounds

- Blinded single reviewer
- Determine change and direction of change of primary outcome

Comparison of trial participants to PCORnet

- Patients at PCORnet sites that participate in PKIDS
- Patients at PCORnet sites that do not participate in PKIDS



* Participants who withdraw but permit data collection will remain in the analysis cohort
 ** Participants did not receive URS, SWL, or PCNL
 *** Cumulative allocation is by patient side
¹ Cumulative allocation is by patient side
² Complete means US studies either reported 'No stone present' OR "had measured stone size"

Participant characteristics

Characteristics	URS (n = 1070)	SWL (n = 197)	PCNL (n = 93)
Median age in years, (IQR)	15.6 (12.6, 17.3)	15.6 (12.5, 17.6)	15.0 (11.8, 17.5)
Female sex, n (%)	659 (61.6%)	103 (52.3%)	39 (45.3%)
Race, n (%)			
White	834 (77.9%)	153 (77.7%)	54 (62.8%)
Black	42 (3.9%)	3 (1.5%)	2 (2.3%)
Asian	15 (1.4%)	1 (0.5%)	1 (1.2%)
Hispanic ethnicity, n (%)	124 (11.6%)	20 (10.2%)	18 (20.9%)
Number of stones in treated kidney, median (IQR)	1 (1, 2)	1.00 (1, 2)	2.0(1.0, 3.0)
Largest stone size in treated kidney, mm, median (IQR)	6 (4, 9)	7.00 (6, 9)	14.0(8.5, 20.0)
Stone Location			
No stone	63 (5.9%)	2 (1.0%)	1 (1.2%)
Lower pole kidney	198 (18.5%)	68 (34.5%)	25 (29.1%)
Non-lower pole kidney	311 (29.1%)	98 (49.7%)	46 (53.5%)
Ureter (includes UPJ)	480 (44.9%)	28 (14.2%)	13 (15.1%)
Primary indication for surgery			
Elective	111 (10.4%)	69 (35.0%)	4 (4.7%)
Pain	702 (65.6%)	75 (38.1%)	26 (30.2%)
UTI	207 (19.3%)	50 (25.4%)	48 (55.8%)


Three patients had SWL for stones >15mm

URS vs SWL

In pediatric patients with a total renal stone burden ≤ 20 mm, clinicians may offer SWL or URS as first-line therapy.
Level C


URS vs SWL

Covariate balance before and after propensity score weighting




URS vs SWL: overall treatment effect

No difference in stone clearance



URS vs SWL: HTE by size and location

No difference in stone clearance (remaining uncertainty 10-15mm)



Impact of URS Compared to SWL on PROs of Physical, Emotional, and Social Health at One week after Surgery


PRO	Procedure	Baseline effect (β , 95% CI)	Procedure effect (β , 95% CI)
Urinary symptoms	URS	0.5 (0.36, 0.65)	5.86 (3.32, 8.39)
Anxiety	URS	0.73 (0.58, 0.88)	2.7 (-0.12, 5.52)
Pain Intensity	URS	0.34 (0.12, 0.56)	4.76 (1.6, 7.91)
Pain Interference	URS	0.33 (0.2, 0.47)	8.09 (4.73, 11.45)
Peer Relationships	URS	0.67 (0.5, 0.85)	-1.22 (-3.64, 1.19)
Sleep Disturbance	URS	0.68 (0.51, 0.84)	1.37 (-1, 3.73)
Stress Experiences	URS	0.68 (0.6, 0.77)	1.42 (-0.57, 3.42)

**PCNL
vs
URS
(not SWL)**

For total renal stone burden >20 mm, both PCNL and SWL are acceptable. If SWL is used, a ureteral stent or nephrostomy tube should be placed.


Expert Opinion

PCNL vs URS: Covariate balance before and after propensity score weighting




PCNL vs URS: Overall treatment effect

No difference in stone clearance



PCNL vs URS: THE by size and location

Greater stone clearance for stones >15mm



Impact of PCNL Compared to URS on Patient-Reported Outcomes of Physical, Emotional, and Social Health at One week after Surgery

PRO	Procedure	Baseline effect (β , 95% CI)	Procedure effect (β , 95% CI)
Urinary symptoms	PCNL	0.31 (0.21, 0.4)	-6.37 (-11.71, -1.03)
Anxiety	PCNL	0.61 (0.54, 0.68)	-5.74 (-9.26, -2.22)
Pain Intensity	PCNL	0.26 (0.19, 0.33)	-5.42 (-10.38, -0.46)
Pain Interference	PCNL	0.24 (0.17, 0.31)	-5.88 (-11.02, -0.75)
Peer Relationships	PCNL	0.67 (0.6, 0.74)	1.63 (-1.94, 5.2)
Sleep Disturbances	PCNL	0.53 (0.45, 0.6)	-5.57 (-8.56, -2.58)
Stress Experiences	PCNL	0.66 (0.6, 0.73)	-7.9 (-13.13, -2.67)


The PKIDS trial supports revision of AUA guidelines

- 1) A new size threshold of 15mm for kidney stones
- 2) Recommend SWL over URS for stones <10mm
- 3) Consider possible greater stone clearance and worse patient experiences with URS for kidney stones 10-15mm
- 4) Remove SWL from guidelines for stones >15mm
- 5) Recommend PCNL over URS for stone >15mm


Internal & External Validity and Generalizability

- 5.4% of stone clearance outcomes changed on central review
 - Bias towards decreasing stone clearance
 - Non-differential across modalities
- No change in direction or statistical significance of point estimates on imputed data analysis


Internal & External Validity and Generalizability




Internal & External Validity and Generalizability




Internal & External Validity and Generalizability



Internal & External Validity and Generalizability



Internal & External Validity and Generalizability



Study Design


Prospective observational cohort study

- Embedded in real-world clinical care
- Greater generalizability
- Threats of bias and unmeasured confounding

Why not a RCT?

- Lack of clinical equipoise
 - treatment is heavily influenced by surgeons' experience, training, and local practices.
 - Surgeons and patients may be unwilling to have surgical decisions determined by chance alone → failure to enroll

Study Design



Enhancing Participation

Introduce the PKIDS trial to *every* patient undergoing surgery

- Trust
 - Operating surgeon introduces study
- Altruism
 - Participation will help families make decisions about surgery by generating knowledge about outcomes that matter most to them
- Financial motivation
 - \$100 compensation
- Burden
 - No study visits
 - Questionnaires can be completed remotely

Retention/Data Missingness

Ultrasound completion reflects real-world care in non-Covid times

- Need to link to real-world clinical outcomes

Very good but not excellent capture of technical aspects of surgery

- Need better ways to recognize missing data at the point of care within time window of ascertainment and intervene

Implementation

Changing care needs more than improved shared decision making

Surgeon and patients

- Informing of evidence and understanding priorities but...

Use of SWL and PCNL determined by

- Surgeon training and skill
- Surgeon bias
- Equipment availability
- Equipment type



If you were
a Kidney
I'd Be your
Stone

